Oncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugated Products: Draft Guidance
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
May 29, 2026
May 29, 2026
c281f7a3-ef1f-4ee6-a357-dcddce26d99b
Related Documents
Early-Phase IND Protocol Recommendations for Solid Tumors; Draft Guidance for Industry
Guidance DocumentNovember 10, 2026Office of the Commissioner
Monoclonal Antibodies: Streamlined Nonclinical Safety Studies: Draft Guidance for Industry
Guidance DocumentDecember 2, 2025Center for Drug Evaluation and Research
Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical Development: Draft Guidance for Industry
Guidance DocumentAugust 19, 2025Office of the Commissioner
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.